IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
CSL Limited
CSL is a Public Company that generates the majority of its income from the Pharmaceutical Product Manufacturing industry. In 2025 the company generated total revenue of $23,716,525,000 including sales and other revenue. In 2025 CSL had 29,000 employees including employees from all subsidiaries under the company's control. The Chief Executive of CSL is Mr Gordon Naylor whose official title is Chief Executive Officer & Managing Director. The Chairman of CSL is Dr Brian McNamee whose official title is Independent Non-Executive Chairman. CSL Limited develops and manufactures vaccines and plasma protein biotherapies. The company operates through four business units: CSL Behring - This unit is involved in the research, development, production and distribution of plasma-derived and recombinant products that are used to manufacture coagulation therapies to treat haemophilia, critical care products for shock in trauma treatment, immunoglobulins for infection treatment and autoimmune diseases. Plasma is also used in wound treatment therapies such as burn treatment. Human blood plasma is sourced from its collection centres and commercial purchases through CSL Plasma. Seqirus - This unit produces and distributes biotherapeutic products including influenza vaccines, prescription medicines, anti-venoms and in-licensed pharmaceuticals to treat and prevent serious human medical conditions. CSL Plasma - CSL Plasma operates one of the world’s largest and most sophisticated plasma collection networks, with more than 300 plasma collection centers in U.S., Europe and China. Plasma collected at CSL Plasma facilities are used by CSL Behring for the purpose of manufacturing and delivering its therapies to people in more than 100 countries. CSL Vifor - Committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease. This is supported by its founding heritage and expertise in iron deficiency therapy, helping to support a broad range of patients in need.
Access this data your way
The CSL Limited Industry analysis is available in multiple formats to fit seamlessly into your workflow.
API Data Delivery
Feed trusted, human-driven industry intelligence straight into your platform.
Integrations
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
What's included in this industry analysis
IBISWorld's research coverage on the CSL Limited includes market sizing, forecasting, data and analysis. The most recent publication will be as current as of March 2026.
Company Details
What’s this enterprise profile about?
CSL Limited, trading as CSL, operates under the ABN 99 051 588 348 and was incorporated on 01 April 1991. CSL Limited trades on the Australian Securities Exchange under the ticker code ASX:CSL. CSL Limited primarily operates in the Pharmaceuticals Wholesaling industry in Australia.
Key Personnel
What’s included in the Key Personnel chapter?
The Key Personnel chapter outlines the principal leadership positions within CSL Limited, including the Chairman, Board members, Chief Executive Officer, and other key management personnel. It provides an overview of the company’s governance and executive structure, along with a breakdown of gender diversity across leadership roles, offering insight into the composition of the organisation’s senior team.
Financials
What’s included in the Financials chapter?
The Financials chapter presents CSL Limited’s historical financial performance, including detailed profit and loss statements outlining sales revenue, cost of sales, and profitability. It also incorporates balance sheet data, providing a breakdown of assets and liabilities, as well as additional financial metrics such as the number of shares on issue. Together, these disclosures offer a comprehensive view of the company’s financial position and performance over time.
Growth & Ratios
What’s included in the Growth & Rations chapter?
The Growth & Ratios chapter provides historical data on key financial performance indicators, enabling an assessment of the company’s operational efficiency, profitability, and financial structure over time. Metrics covered include return on equity, return on assets, profit margins, revenue per employee, as well as gearing and leverage ratios, offering a comprehensive view of performance trends and capital management.
Operating Segments
What’s included in the Operating Segments chapter?
The Operating Segments chapter provides an overview of the revenue composition and asset allocation across the various industries in which CSL Limited operates. It offers insights into how the company’s financial performance is distributed among its core business segments, highlighting the relative contribution of each industry to total revenue.
Competitor Benchmarking
What’s included in the Competitor Benchmarking chapter?
The Competitor Benchmarking chapter includes a comparative assessment of CSL Limited’s key financial, growth, and valuation ratios against industry averages to evaluate its competitive position. It analyses valuation metrics such as price-to-earnings, price-to-book, enterprise value to EBITDA, and enterprise value to sales, alongside core financial indicators including liquidity ratios and profitability measures.
Industries of Operation
What’s included in the Industries of Operation chapter?
The Industries of Operation chapter outlines CSL Limited’s market share across the industries in which it operates. Each industry profile includes a comprehensive overview featuring data on total market size, the number of enterprises, industry concentration levels, and overall turnover. This analysis provides context for the company’s competitive position and scale within each relevant market.
Shareholders
What’s included in the Shareholders chapter?
The Shareholders chapter provides a breakdown of the ownership structure of CSL Limited, identifying key shareholders and outlining their respective ownership interests. This section offers insight into the concentration of shareholdings, the presence of institutional or strategic investors, and the overall distribution of equity within the company.
Subsidiaries
What’s included in the Subsidiaries chapter?
The Subsidiaries chapter provides an overview of the companies and business entities that are wholly or partially owned by CSL Limited. It outlines the ownership structure of each subsidiary, offering insight into the broader corporate group and how these entities contribute to the company’s overall activities and performance.
History
What’s included in the History chapter?
The History chapter presents a overview of CSL Limited’s development, highlighting key milestones and significant corporate events since its incorporation. It includes the company’s incorporation date and outlines major strategic, operational, and structural developments, providing context for its evolution and current market position.
Trusted by industry professionals
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
Frequently Asked Questions
What is CSL Limited?
CSL Limited develops and manufactures vaccines and plasma protein biotherapies. The company operates through four business units: CSL Behring - This unit is involved in the research, development, production and distribution of plasma-derived and recombinant products that are used to manufacture coagulation therapies to treat haemophilia, critical care products for shock in trauma treatment, immunoglobulins for infection treatment and autoimmune diseases. Plasma is also used in wound treatment therapies such as burn treatment. Human blood plasma is sourced from its collection centres and commercial purchases through CSL Plasma. Seqirus - This unit produces and distributes biotherapeutic products including influenza vaccines, prescription medicines, anti-venoms and in-licensed pharmaceuticals to treat and prevent serious human medical conditions. CSL Plasma - CSL Plasma operates one of the world’s largest and most sophisticated plasma collection networks, with more than 300 plasma collection centers in U.S., Europe and China. Plasma collected at CSL Plasma facilities are used by CSL Behring for the purpose of manufacturing and delivering its therapies to people in more than 100 countries. CSL Vifor - Committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease. This is supported by its founding heritage and expertise in iron deficiency therapy, helping to support a broad range of patients in need.
What industry does CSL Limited operate in?
CSL Limited, trading as CSL, is a Public Company that generates the majority of its income from the Pharmaceuticals Wholesaling industry in Australia.
Where is CSL Limited located?
Murray Cod Australia Limited company is based at 655 Elizabeth Street, Melbourne, Victoria, Australia.
Who is the CEO of CSL Limited?
The Chief Executive Officer & Managing Director of CSL Limited is Brian McNamee and the Chief Executive Officer & Managing Director is Gordon Naylor.
What was CSL Limited’s revenue in 2025?
In 2025, CSL Limited generated total revenue of approximately $23.7 billion.
Cut through the noise with intelligence you can trust
